Infant Bacterial Therapeutics AB (publ) (STO:IBT.B)
43.45
-1.60 (-3.55%)
At close: Dec 5, 2025
STO:IBT.B Revenue
Infant Bacterial Therapeutics AB had revenue of -1.00K SEK in the twelve months ending September 30, 2025. In the year 2024, Infant Bacterial Therapeutics AB had annual revenue of 4.00K, down -94.81%.
Revenue (ttm)
-1.00K
Revenue Growth
-94.81%
P/S Ratio
-585,333.20
Revenue / Employee
-125.00
Employees
8
Market Cap
585.33M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.00K | -73.00K | -94.81% |
| Dec 31, 2023 | 77.00K | 65.00K | 541.67% |
| Dec 31, 2022 | 12.00K | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Getinge AB | 35.85B |
| Swedish Orphan Biovitrum AB | 27.85B |
| Medicover AB | 25.67B |
| Elekta AB | 17.57B |
| Asker Healthcare Group AB | 16.41B |
| AddLife AB | 10.53B |
| Nolato AB | 9.57B |
| Vitrolife AB | 3.51B |